Sharemaestro company-news research for Johnson & Johnson (JNJ), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
GER
Germany
Measured evidence
Company news sentiment
JNJ news sentiment
Johnson & Johnson
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone69Neutral is 50
Constructive news tone
82/100 evidence confidence
100% direct company focus
15 current stories across 1 publishers
Current company news
Positive news being faded
Constructive news tone is drawn from 15 fresh independent stories, including 15 company-specific items across 1 publishers.
Latest source headline Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In finance.yahoo.com · 12 Aug 2026 21:13What supports the read
15 current stories are mapped specifically to JNJ.
Cross-story agreement is 89/100, indicating a comparatively coherent tape.
What tempers the read
Only 1 publisher currently contribute to the measured read.
Constructive headlines are not being rewarded by price, which raises a rejection flag.
69/100
Weighted toneConstructive news tone
82/100
Evidence confidencehigh confidence
100%/100
Company focus15 direct stories
89/100
Evidence agreement11/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth100
14.04 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness77
recency-weighted evidenceAgreement89
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Constructive headlines are not being rewarded by price, which raises a rejection flag.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment confirms active trendPositive but stretched
News subjects
What is shaping the score
Earnings7810 stories · 67%
Analyst action672 stories · 13%
Regulatory and legal642 stories · 13%
Market update651 stories · 7%
Source mix
Where the evidence comes from
finance.yahoo.com7415 stories · 100%
Recurring subjects
Subjects appearing most often
Fda Approval6Earnings6Healthcare5Revenue Growth4Price Target4Medtech4Robotic Surgery3Guidance3Earnings Per Share3Biotech3
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#185Tone
finance.yahoo.comDirect company coverage
Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return
EarningsMedical EquipmentRevenue GrowthShare PriceShareholderSplit
- Published
- 12 Aug 2026 21:13
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#267Tone
finance.yahoo.comDirect company coverage
Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher growth therapeutic and medtech areas that are important for its lo
CardiovascularClinical TrialsMedtechNeurosciencePharmaceuticalsRevenue Growth
- Published
- 12 Aug 2026 16:11
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#377Tone
finance.yahoo.comDirect company coverage
Intuitive Surgical: Oppenheimer now bullish, sees competition being "crowded out"
Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of "Crowding Out Competitors" is strategically smart. Analyst Suraj Kalia said the change reflects "a more nuanced risk-reward assessment at these levels." On the positive side, the firm views U.S. competition as a "non-factor," with field checks suggesting "some unique workflow challenges for Ottava that limit long-term appeal" and real-estate issues for Hugo. It added that Intuitive's customized price-volume contracts complicate c
HealthcarePrice TargetPrice TargetRobotic SurgeryUpgrade Downgrade
- Published
- 12 Aug 2026 12:59
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#458Tone
finance.yahoo.comDirect company coverage
Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall
This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator
Price TargetPrice TargetRobotic SurgeryUpgrade Downgrade
- Published
- 12 Aug 2026 12:25
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#563Tone
finance.yahoo.comDirect company coverage
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson ("J&J") and is a member of J&J's Executive Committee, where he leads research and development across oncology, immunology, neuroscie
BiotechFda ApprovalMashPress Releases
- Published
- 12 Aug 2026 12:00
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#690Tone
finance.yahoo.comDirect company coverage
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?
AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory
BiotechCompetitionEarningsFda ApprovalImmunology
- Published
- 11 Aug 2026 16:54
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#786Tone
finance.yahoo.comDirect company coverage
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa
EarningsInnovative MedicineLitigationMedtechPatent ExpirationShare Price
- Published
- 11 Aug 2026 13:12
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#873Tone
finance.yahoo.comDirect company coverage
What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders
In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these developments highlight Johnson & Johnson's effort to reposition around higher-growth innovative medicines and me
Fda ApprovalLitigationMedtechOncologyRevenue GrowthRobotics
- Published
- 11 Aug 2026 00:20
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#985Tone
finance.yahoo.comDirect company coverage
Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?
Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on track to generate more than $100 billion in annual revenue for the first time in its 140-year history. Medtronic (NYSE:MDT), meanwhile, ended fiscal 2026 with its fastest annual revenue growth in a decade. Several newer products ar
EarningsEarnings GrowthEarnings Per ShareGuidanceHealthcareMedical Devices
- Published
- 10 Aug 2026 22:36
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1084Tone
finance.yahoo.comDirect company coverage
Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history. Abbott Laboratories (NYSE:ABT) also beat its quarterly estimates in its fiscal Q2 2026 results while also raising its annual profit forecast, with strong
DiagnosticsEarningsEarnings GrowthEarnings Per ShareGuidanceHealthcare
- Published
- 10 Aug 2026 20:49
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1154Tone
finance.yahoo.comDirect company coverage
Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY
During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the… Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these… I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a
Balance SheetBiotechFda ApprovalFourth QuarterHealthcareM A
- Published
- 10 Aug 2026 18:07
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1287Tone
finance.yahoo.comDirect company coverage
ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?
Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple. Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 1
EarningsEarnings Per ShareFda ApprovalGuidanceMedical InstrumentsRevenue Growth
- Published
- 10 Aug 2026 14:42
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1360Tone
finance.yahoo.comDirect company coverage
Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?
Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon relationships, and a rapidly expanding da Vinci 5 platform. The question for investors is not whether OTTAVA can become a viable product, but whether Johnson & Johnson (NYSE:JNJ) can convert its differ
Fda ApprovalFinancial ResultsHealthcareMedtechRobotic Surgery
- Published
- 10 Aug 2026 12:42
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1465Tone
finance.yahoo.comDirect company coverage
ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers
Agreement supports ACCESS-affiliated ASCs in adopting the CARTO™ System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio agreement with Johnson & Johnson to support the adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers (ASC) across the United States. The agreement encompasses an integrated portfolio of three-dim
Ambulatory Surgery CentersCardiovascular CareElectrophysiology
- Published
- 10 Aug 2026 11:00
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1565Tone
finance.yahoo.comDirect company coverage
Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of litigation over alleged health risks tied to the company's talc-based products. The settlement follows years of high profile trials and failed bankruptcy attempts related to the talc claims. This resolution removes a long running legal overhang and brings more clarity for Johnson & Johnson investors. Consider broadening your research to o
Balance SheetConsumer HealthLegal IssuesSettlement
- Published
- 07 Aug 2026 19:10
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.